In the Choudhury et al. study, CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib were found to halt clonogenic growth of established meningioma cell lines (CH157-MN, IOMM-Lee), which were classified as HM group, and IE patient-derived cell lines [52]. The gene discussed is CDK4; the disease is meningioma.